Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Buy
59
BDX Quote, Financials, Valuation and Earnings
Last price:
$225.24
Seasonality move
:
6.25%
Day range:
$225.30 - $227.87
52-week range:
$218.75 - $249.89
Dividend yield:
1.72%
P/E ratio:
38.12x
P/S ratio:
3.26x
P/B ratio:
2.53x
Volume:
1.8M
Avg. volume:
2.1M
1-year change:
-6.81%
Market cap:
$65.5B
Revenue:
$20.2B
EPS (TTM):
$5.94
Analysts' Opinion
-
Consensus RatingBecton Dickinson & has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Becton Dickinson & has an estimated upside of 23.67% from its current price of $226.44.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $226.44.
Fair Value
-
According to the consensus of 0 analysts, Becton Dickinson & has 23.67% upside to fair value with a price target of -- per share.
BDX vs. S&P 500
-
Over the past 5 trading days, Becton Dickinson & has underperformed the S&P 500 by -2.19% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Becton Dickinson & does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Becton Dickinson & has grown year-over-year revenues for 7 quarters straight. In the most recent quarter Becton Dickinson & reported revenues of $5.4B.
Earnings Growth
-
Becton Dickinson & has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Becton Dickinson & reported earnings per share of $1.45.
Enterprise value:
83.4B
EV / Invested capital:
1.81x
Price / LTM sales:
3.26x
EV / EBIT:
32.92x
EV / Revenue:
4.13x
PEG ratio (5yr expected):
1.93x
EV / Free cash flow:
27.15x
Price / Operating cash flow:
21.44x
Enterprise value / EBITDA:
17.31x
Gross Profit (TTM):
$9.1B
Return On Assets:
3.13%
Net Income Margin (TTM):
8.45%
Return On Equity:
6.63%
Return On Invested Capital:
3.91%
Operating Margin:
14.59%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $18.9B | $19.4B | $20.2B | $5.1B | $5.4B | |
| Gross Profit | $8.5B | $8.2B | $9.1B | $1.7B | $2.5B | |
| Operating Income | $2.5B | $2.4B | $2.9B | $485M | $793M | |
| EBITDA | $4.4B | $4.4B | $4.8B | $881M | $1.3B | |
| Diluted EPS | $5.88 | $4.96 | $5.94 | $0.37 | $1.45 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $9B | $8.8B | $8.1B | $8.7B | $10.5B | |
| Total Assets | $54B | $53.9B | $52.9B | $52.8B | $57.3B | |
| Current Liabilities | $5.8B | $6.6B | $7.8B | $6.6B | $9B | |
| Total Liabilities | $30.2B | $30.2B | $27.7B | $27B | $31.4B | |
| Total Equity | $23.8B | $23.7B | $25.3B | $25.8B | $25.9B | |
| Total Debt | $17.9B | $17.6B | $16.1B | $15.9B | $20.1B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $2.6B | $3B | $3.8B | $1.3B | $1.2B | |
| Cash From Investing | -$3.2B | -$716M | -$5.5B | $137M | -$3.9B | |
| Cash From Financing | -$591M | -$2B | $2.1B | -$998M | $124M | |
| Free Cash Flow | $1.7B | $2.1B | $3.1B | $1B | $882M | |
BDX
Sector
Market Cap
$65.5B
$45.6M
Price % of 52-Week High
90.62%
45.55%
Dividend Yield
1.72%
0%
Shareholder Yield
1.34%
-0.74%
1-Year Price Total Return
-6.82%
-31.35%
Beta (5-Year)
0.408
0.772
Dividend yield:
1.72%
Annualized payout:
$3.80
Payout ratio:
64.52%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$226.00
200-day SMA
Sell
Level
$234.27
Bollinger Bands (100)
Sell
Level
226.8 - 239.46
Chaikin Money Flow
Buy
Level
383.3M
20-day SMA
Buy
Level
$223.74
Relative Strength Index (RSI14)
Buy
Level
51.16
ADX Line
Buy
Level
13.64
Williams %R
Neutral
Level
-41.0853
50-day SMA
Sell
Level
$229.90
MACD (12, 26)
Sell
Level
-0.68
25-day Aroon Oscillator
Buy
Level
12
On Balance Volume
Neutral
Level
269.1M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.2563)
Buy
CA Score
(Annual)
Level (-0.2538)
Buy
Beneish M-Score
(Annual)
Level (-2.5661)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-1.0561)
Buy
Piotroski F Score
(Annual)
Level (7)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.
Stock Forecast FAQ
In the current month, BDX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BDX average analyst price target in the past 3 months is --.
-
Where Will Becton Dickinson & Stock Be In 1 Year?
According to analysts, the consensus estimate is that Becton Dickinson & share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Becton Dickinson &?
Analysts are divided on their view about Becton Dickinson & share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Becton Dickinson & is a Sell and believe this share price will drop from its current level to --.
-
What Is Becton Dickinson &'s Price Target?
The price target for Becton Dickinson & over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BDX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Becton Dickinson & is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BDX?
You can purchase shares of Becton Dickinson & via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Becton Dickinson & shares.
-
What Is The Becton Dickinson & Share Price Today?
Becton Dickinson & was last trading at $225.24 per share. This represents the most recent stock quote for Becton Dickinson &. Yesterday, Becton Dickinson & closed at $226.44 per share.
-
How To Buy Becton Dickinson & Stock Online?
In order to purchase Becton Dickinson & stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 7.46% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is down 0.66% over the past day.
Sell
48
VRNA alert for Dec 24
Verona Pharma PLC [VRNA] is down 0.53% over the past day.
